PHAR vs LTGO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PHAR · Pharming Group$11.54 ▼ 5.18%
LTGO · Latigo Biotherapeutics$13.00 ▼ 1.81%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PHAR +5.4%
- LTGO -28.8%
Head to head
| Metric | PHAR | LTGO |
|---|---|---|
| Price | $11.54 | $13.00 |
| Change today | ▼ 5.18% | ▼ 1.81% |
| Market cap | $816.78M | $861.89M |
| Return, 3 months | +0.7% | -40.9% |
| Return, year to date | -34.7% | – |
| Return, 1 year | -29.0% | – |
| P/E (TTM) | 35.0 | – |
| P/B | 2.8 | 2.2 |
| P/E percentile vs own 5y | 77th | 89th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +20.8% | – |
| Net profit growth (YoY) | +197.1% | +15.5% |
| Gross margin | 85.1% | – |
| Operating margin | 6.7% | – |
| Net margin | 6.3% | – |
| Return on equity | 8.7% | -27.2% |
| Analyst target vs. price | +238.0% | +343.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 45 | 41 |
| 30-day volatility | 59.3% | 84.6% |
| Max drawdown, 1 year | -57.0% | -49.6% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LTGO is the largest of the group by market value.
- PHAR has been the calmest stock over the last 30 days.